"分析师转行做教培"刷屏 近日，中泰证券研究所前员工周寒阳的离职感言及去向引发行业热议。在感谢公司栽培并告别同事后，他透 露："我已转行从事高中科创教培（涵盖实验设计、数据获取、科研报告写作及自主招生面试辅导等全流程服 务）。江湖路远，愿各自珍重。" 值得一提的是，由于该分析师离职前研究的是电新行业，也有一些市场言论认为，"电新分析师转行做教培"是 电新板块底部的信号。不过，记者了解到，该人士转行主要是个人选择。 记者注意到，近年来，不少券商发力研究业务，在研究团队方面对于总量、人工智能、计算机、传媒、金工等 行业的配置较多。一位分析师告诉记者，近几年机构持仓大头是科技，因此各个研究所对人工智能、机械等科 技行业的人员增配较多。 "没有冷门的行业，只有不会策划的分析师。"一家中型券商研究所所长告诉券商中国记者，一般来说强势行业 确实会进行超配，但每个行业都有自身的周期，研究所也习惯了这种周期波动，一般不会刻意因此对各个行业 的研究力量进行调整。 "再见领导同事，我要转战教培行业了！"近日，一位中泰证券研究所前员工的离职感言在业内刷屏。 券商中国记者注意到，证券行业从业人数在2023年见顶后进入持续减员通道。最 ...

进入晨星小程序，轻松掌握更多基金信息！ | 基金代码： | 002651 | | --- | --- | | 基金类型： | 积极债券 | | 基准指数： | 中国积极债券基准指数 | | 成立日期： | 2016-06-13 | | --- | --- | | 基金规模（亿元）： | 29.03 | | 基金规模日期： | 2025-03-31 | | 晨星三年评级： | | | 晨星五年评级： | | | 基金经理： | 孔令超 | | 股票投资风格箱： | | 东方红汇利债券基金由投研经验丰富的基金经理孔令超掌舵，以纯债打底，叠加灵活配置可转债和股票增厚收益，力求为投资者在长期创造稳健的投资回报。股票方面，基金 经理首先筛选出估值较低、在行业中具有竞争优势的个股，然后自上而下确定行业配置比例。可转债方面，基金经理倾向于在转债估值较低时增加配置，以偏债型和平衡型为 主。纯债部分以中短久期的高等级信用债个券配置为主，利率债的配置比例一般在 30% 以内，杠杆策略整体稳健。截至 2025 年 6 月底，该基金在基金经理的管理期内获得了 4.42% 的年化回报率，在同类积极债券基金中排名前 27% 。该基金年度 ...

Core Viewpoint - The gold and jewelry market is undergoing significant changes due to persistently high gold prices, leading to shifts in consumer behavior and market dynamics [4][6][12]. Group 1: Market Trends - The market is witnessing a trend towards lower-priced products, with a notable decline in the sales of heavier gold items, while lighter gold bars (10g to 30g) are gaining popularity among consumers [6][11]. - Retailers are adjusting their product offerings, emphasizing lighter and higher-value items, such as silver, pearls, jade, and platinum, which were previously considered secondary products [6][10]. - The introduction of innovative products, like the collaboration between brands and local cultural elements, reflects the industry's shift towards lightweight and high-value offerings [6][10]. Group 2: Channel Restructuring - The industry is experiencing a phenomenon of store closures, particularly in rural areas, as consumer spending power diminishes in smaller towns [7][10]. - The emergence of small-scale "goldsmith" shops caters to consumers seeking unique, handcrafted items, indicating a deeper market segmentation [10][11]. - The market is evolving with a demand for low-cost models, necessitating regulatory oversight to ensure compliance and product quality [10][11]. Group 3: Consumer Behavior and Trust - High gold prices have altered consumer perceptions, leading to a cautious approach towards purchasing, with a decline in demand for larger gold items [11][12]. - The introduction of gold-plated silver products has raised concerns about industry integrity, prompting discussions on ensuring accurate metal content and maintaining consumer trust [11][12]. - There is a generational divide in purchasing preferences, with younger consumers more open to paying for design and craftsmanship, while older consumers prioritize the intrinsic value of gold [11][12]. Group 4: Brand Strategies - The industry is undergoing structural adjustments, with some brands focusing on high-end offerings while others seek differentiation and refined operations [12][14]. - Brands are encouraged to adopt rational store opening strategies, emphasizing quality over quantity in their market presence [14]. - The market's evolution necessitates brands to embrace innovation, uphold integrity, and accurately position their value to thrive in a challenging environment [14].

Core Viewpoint - The recent announcement by the Shanghai Medical Insurance Bureau regarding the adjustment of coronary stent reimbursement standards is expected to provide new ideas for diversified payment methods in the industry [1][5]. Group 1: Policy Changes - The new reimbursement rules categorize coronary stents into three payment categories: full reimbursement for selected products, a reduced maximum payment for non-selected products, and a percentage payment for products outside the selection [1][5]. - The policy aims to create a competitive environment for high-value innovative devices alongside selected products, potentially increasing their market presence [1][5]. Group 2: Market Impact - The shift in policy is seen as beneficial for non-selected products, allowing hospitals more freedom to use them after fulfilling procurement obligations for selected products [2][5]. - The coronary stent market has experienced significant price reductions due to centralized procurement, with average prices dropping from approximately 13,000 yuan to around 700 yuan [3][4]. Group 3: Industry Dynamics - The coronary intervention medical device sector is highly competitive, with domestic and international companies vying for market share through technological advancements and product offerings [6][7]. - Companies like Sientra have reported substantial growth in sales of their stent products, indicating a positive response to the new procurement policies [6][7]. Group 4: Future Outlook - The industry is expected to focus on innovation and international expansion as key strategies for growth, with companies exploring new business models and enhancing product lines [7][8]. - The global medical device market is substantial, with opportunities for Chinese companies to expand their presence internationally, driven by policy adjustments and technological advancements [8].

Core Viewpoint - The company, Helin Micro-Nano (688661.SH), is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global brand recognition, competitiveness, and capital structure [1] Group 1: H-Share Listing Plans - The company is in discussions with intermediaries regarding the specifics of the H-share listing, which is still in the planning stage and subject to board and shareholder approval, as well as regulatory review [1][2] - The H-share listing is aimed at optimizing capital structure and expanding financing channels while maintaining the current control structure of the company [1] Group 2: Previous Fundraising Activities - Helin Micro-Nano was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 29, 2021, with an issuance of 20 million shares at a price of 17.71 yuan per share, raising a total of 354 million yuan [2] - The company raised a net amount of 312 million yuan after deducting issuance costs, which was 15.3 million yuan less than the planned amount [2] - The funds raised were allocated to various projects, including 141 million yuan for MEMS precision electronic components expansion and 110 million yuan for R&D center construction [2] Group 3: Financial Performance - In 2024, the company reported revenue of 569 million yuan, a year-on-year increase of 99.13%, while the net profit attributable to shareholders was -8.71 million yuan, an improvement from -20.94 million yuan the previous year [4] - The company also reported a net cash flow from operating activities of 14.05 million yuan, compared to -11.06 million yuan in the previous year [4]

Group 1 - The core viewpoint of the news is that Yihai Kerry Group's brand, Jinlongyu, has maintained its leading position in the edible oil market for fifteen consecutive years, achieving a score of 698.5 in the 2025 China Brand Power Index (C-BPI) [1][2] - Jinlongyu also ranked first in the flour and rice categories, showcasing the company's strong positioning across the entire grain and oil industry chain [1] - The report highlights the strong brand matrix of Yihai Kerry Group, with its sub-brands, Hu Jihua and Xiang Manyuan, also performing well in the edible oil category, indicating a synergistic effect within the brand portfolio [1] Group 2 - Yihai Kerry Group ranked 32nd in the 2025 China Listed Companies Brand Value List, with a brand value of 153.608 billion yuan, reflecting its strong brand influence [2] - The company has successfully maintained its leadership in the edible oil sector while making new breakthroughs in the flour and rice markets through brand focus and product innovation [2] - The resilience of the brand and diversified layout is expected to create greater market opportunities for the company amid the trend of consumer upgrades [2]

（原标题：倾听尼山2025｜彭国翔：精神性传统之间亟须对话与交融） 从"良知"到"斯文"，从"多元共生"到"内在超越"，彭国翔的学术探索始终指向一个核心命题：在全球化 与反全球化交织、技术同质化与文化多样性并存的时代，儒学不仅要自我更新，更要敢于为人类精神性 编者按： 在全球性精神危机与文化断裂日益加深的当下，哲学不再只是学术的分类或概念体系，而是一种回应现 实困境的方式。 对于儒学的这一精神特质，彭国翔以"内在超越"这一概念为例，特别做出了说明。他认为："一个人若 相信这个世界有个价值根源，并且这个价值源头同时在我们心中扎根，与我们的本心和良知是一体的关 系，那他的精神世界就既不同于完全世俗化的人，也不同于一神教的信仰者。"这种"内在超越"或"内向 超越"不是概念游戏，而是一种切实可感的生命体验，是中国哲学特有的精神气质。他援引王阳明的诗 句——"不离日用常行内，直造先天未画前"——以说明儒学"超越"（天理）与"内在"（良知）的一体连 续，而这就是《中庸》所谓的"极高明而道中庸"。 2025 年 7 月 9 日至 10 日，第十一届尼山世界文明论坛将在山东曲阜举办。从 2010 年 9 月创立至今，尼山论 ...

绝味食品2017年上市以来一直热衷于对外投资，上述基金只是其投资版图的冰山一角。根据公开信息， 此次延期的湖南肆壹伍基金目前对外投资7个项目，其中不少公司最后一轮融资停留在2021年。 从整体来看，2024年绝味食品投资净收益为-1.6亿元，比2023年多亏损0.44亿元。在销售下滑、门店减 少的同时，绝味食品规模庞大的投资中蕴藏的风险同样不容忽视。 出品：新浪财经上市公司研究院 作者：浪头饮食/ 郝显 近日，绝味食品（维权）接连发布公告对旗下私募股权基金进行延期。 6月27日，公司发布公告表示旗下股权投资基金湖南肆壹伍私募股权基金企业（有限合伙）（以下简 称"湖南肆壹伍基金"）存续期即将届满，合伙人会议决定将存续期延长一年。 而在此前的6月19日，公司宣布将旗下广州绝了股权投资基金合伙企业（有限合伙）（以下简称"绝了一 期基金"）存续期再延长一年，这已经是第二次延期。 股权投资基金延期 绝味食品多元化投资成拖累 近日，绝味食品发布公告，称全资子公司参与设立的股权投资基金——湖南肆壹伍私募股权基金企业 （有限合伙）（以下简称"湖南肆壹伍基金"）存续期即将届满，为了保证基金的正常运作和已投资项目 的顺利退出，湖 ...

Core Viewpoint - Lens Technology (300433.SZ) is advancing its H-share IPO process in Hong Kong, aiming to raise approximately 43 billion RMB to enhance its global strategy and diversify its product offerings [1][7]. Group 1: IPO Details - The IPO will involve a base issuance of approximately 262 million shares, with a price range set between 17.38 HKD and 18.18 HKD, potentially raising around 46.63 billion HKD (approximately 43 billion RMB) if the midpoint price is used [1][7]. - The IPO process has progressed rapidly, taking about 100 days from the announcement to the start of the offering [7]. - The offering is set to conclude on July 4, with the price announcement on July 8 and trading commencing on July 9 [8]. Group 2: Strategic Objectives - The company aims to allocate 28% of the raised funds to expand its overseas business and 48% to diversify its product and service offerings [10]. - Lens Technology plans to establish new production lines in Vietnam and Thailand for smart terminal components and smart automotive products, expected to be operational by the end of 2025 [10]. Group 3: Diversification and Revenue Trends - The company is actively reducing its reliance on Apple, with sales to Apple decreasing from 71% in 2022 to 49.45% in 2024 [2][12]. - Revenue from smartphones and computers still constitutes about 82% of total revenue in 2023 and 2024, but the company anticipates further diversification in the coming years [12]. - Lens Technology's revenue has shown consistent growth, with figures of 466.99 billion RMB in 2022, 544.91 billion RMB in 2023, and projected 698.97 billion RMB in 2024, alongside net profits increasing from 24.48 billion RMB to 36.24 billion RMB over the same period [12].

Core Viewpoint - The IPO enthusiasm in the Hong Kong market is rising, with Shanghai Meixin Health Technology Group Co., Ltd. planning to go public, aiming to transform China's medical payment system [1][2]. Company Overview - Shanghai Meixin Health is the largest pharmaceutical multi-payment platform in China, focusing on addressing financing and payment challenges faced by patients, insurers, and pharmaceutical companies [1]. - As of December 31, 2024, the company has served approximately 393 million insurance policies and collaborated with over 140 pharmaceutical companies and more than 90 insurers [1]. Financial Performance - Revenue from 2022 to 2024 was reported as follows: 1.069 billion yuan, 1.255 billion yuan, and 2.035 billion yuan, with a compound annual growth rate of approximately 38% [2]. - Despite revenue growth, the company reported net losses of 446 million yuan, 288 million yuan, and 79 million yuan for the same period, indicating a need for a sustainable profit model [2]. IPO Challenges - The path to IPO has been complicated by legal disputes, including allegations of trade secret infringement from a former partner, which have delayed the listing process [3][4]. - Regulatory scrutiny has increased, with the China Banking and Insurance Regulatory Commission highlighting issues in the short-term health insurance sector, affecting Meixin's product offerings and profitability [4][6]. Market Competition - The medical payment sector is becoming increasingly competitive, with Meixin Health relying heavily on partnerships with pharmaceutical companies and insurers [6]. - The company faces pressure to enhance service quality and innovation to maintain its market position [6]. Future Outlook - Meixin Health plans to deepen collaborations with pharmaceutical companies and insurers, investing in an integrated payment platform to optimize healthcare payments and services [7]. - The company aims to address structural imbalances in the medical payment system while navigating regulatory challenges and profitability issues [8].